| Literature DB >> 31111677 |
Daisuke Harada1, Hidetsugu Asanoi2, Takahisa Noto1, Junya Takagawa1.
Abstract
AIMS: The heterogeneity of heart failure with preserved ejection fraction (HFpEF) represents different pathophysiological paths by which individual patients develop heart failure. The deterioration mechanisms are considered to be mainly left ventricular diastolic dysfunction, right ventricular (RV) systolic function, and RV afterload. It is unclear whether RV distensibility affects the deterioration of HFpEF. Our study aimed to clarify whether impaired RV distensibility is associated with the deterioration of HFpEF. METHODS ANDEntities:
Keywords: HFpEF; Heart failure; Jugular venous pulse; Right ventricular distensibility; Right ventricular dysfunction; Right ventricular systolic pressure
Mesh:
Year: 2019 PMID: 31111677 PMCID: PMC6676302 DOI: 10.1002/ehf2.12460
Source DB: PubMed Journal: ESC Heart Fail ISSN: 2055-5822
Figure 1Study flowchart for patient enrolment in the present study. HFpEF, heart failure with preserved left ventricular ejection fraction; LAVI, left atrial volume index; LVEF, left ventricular ejection fraction; TR, tricuspid regurgitation.
Figure 2Jugular venous pulse. A pulse‐wave transducer (left side) was placed over the neck, above and to the right of the junction of the right clavicle and the manubrium sterni, and held in place manually (right side).
Figure 3Assessment of echocardiography and the jugular venous pulse. The mitral inflow (upper left) and the early diastolic velocities (e′) of the septum (lower left). Tracings of the jugular venous pulse, phonocardiogram, and electrocardiogram (upper right), with subtraction of baseline fluctuations (lower right). (A) A 73‐year‐old man with HFpEF and prior coronary revascularization had a distensible right ventricle characterized by the highest ‘A’ wave and the deepest ‘X’ descent within a single cardiac cycle. (B) An 86‐year‐old woman with HFpEF and chronic atrial fibrillation had a less‐distensible right ventricle characterized by the dominant ‘Y’ descent, with a nadir deeper than that of ‘X’. ECG, electrocardiogram; JVP, jugular venous pulse; PC, phonocardiogram.
Contingency table for evaluation of RV distensibility
| Cardiologist B | ||||
|---|---|---|---|---|
| Distensible right ventricle | Less‐distensible right ventricle | Totals | ||
| Cardiologist A | Distensible right ventricle | 193 | 3 | 196 |
| Less‐distensible right ventricle | 1 | 125 | 126 | |
| Totals | 194 | 128 | 322 | |
Patient characteristics according to right ventricular distensiblity
| Total population ( | Distensible right ventricle ( | Less‐distensible right ventricle ( |
| |
|---|---|---|---|---|
| Age, years | 76 ± 11 | 73 ± 12 | 79 ± 10 | <0.001 |
| Men | 146 (45) | 92 (48) | 54 (42) | 0.361 |
| Heart rate, b.p.m. | 70 ± 11 | 70 ± 11 | 71 ± 11 | 0.165 |
| Prior hospitalization for HFpEF | 62 (19) | 29 (12) | 33 (45) | <0.001 |
| Underlying disorders | ||||
| Hypertension | 281 (87) | 165 (85) | 116 (90) | 0.306 |
| Diabetes mellitus | 65 (20) | 47 (24) | 18 (14) | 0.024 |
| Chronic atrial fibrillation | 74 (23) | 7 (4) | 67 (52) | <0.001 |
| Prior coronary revascularization | 85 (26) | 62 (32) | 23 (18) | 0.005 |
| Medications | ||||
| Beta‐blockers | 163 (51) | 99 (51) | 64 (50) | 0.82 |
| Calcium channel blockers | 175 (54) | 108 (56) | 67 (52) | 0.495 |
| ACE/ARB inhibitors | 228 (71) | 131 (68) | 97 (75) | 0.17 |
| Diuretics | 163 (51) | 54 (27) | 109 (86) | <0.001 |
| NYHA | 2.3 ± 0.5 | 2.2 ± 0.4 | 2.4 ± 0.5 | <0.001 |
| I/II/III/IV | 0/229/93/0 | 0/157/36/0 | 0/72/57/0 | <0.001 |
| Symptoms and signs of HFpEF | ||||
| Dyspnoea on exertion | 304 (94) | 186 (96) | 118 (91) | 0.082 |
| Leg oedema | 132 (41) | 40 (21) | 92 (71) | <0.001 |
| Neck vein dilatation | 90 (28) | 23 (12) | 67 (52) | <0.001 |
| Pleural effusion | 50 (16) | 7 (4) | 43 (33) | <0.001 |
| BNP, pg/dL ( | 181 (83, 318) | 119 (67, 234) ( | 262 (160, 460) ( | <0.001 |
| Creatinine, mg/dL ( | 0.87 (0.66, 1.11) | 0.87 (0.64, 1.09) ( | 0.88 (0.69, 1.15) ( | 0.781 |
| eGFR, mL/min ( | 57 ± 24 | 59 ± 25 ( | 56 ± 22 ( | 0.354 |
| Cardiovascular event | 73 (23) | 25 (13) | 48 (37) | <0.001 |
Data are number of patients (%), median (interquartile range), or mean ± SD. ACE/ARB, angiotensin‐converting enzyme inhibitors/angiotensin‐receptor blockers; BNP, brain natriuretic peptide; HFpEF, heart failure with preserved left ventricular ejection fraction; NYHA, New York Heart Association.
Echocardiographic features according to right ventricular distensiblity
| Total population ( | Distensible right ventricle ( | Less‐distensible right ventricle ( |
| |
|---|---|---|---|---|
| Left ventricular function | ||||
| LVEF, % | 66 ± 8 | 66 ± 9 | 66 ± 8 | 0.715 |
| LVEDD, mm | 48 ± 5 | 49 ± 5 | 47 ± 6 | 0.004 |
| LAVI, mL/m2 | 41 ± 10 | 39 ± 7 | 44 ± 12 | <0.001 |
| E/A ratio of mitral inflow ( | 0.97 ± 0.45 | 0.92 ± 0.38 ( | 1.12 ± 0.59 ( | 0.002 |
| DT of mitral early inflow | 217 ± 63 | 227 ± 58 | 202 ± 66 | <0.001 |
| Average mitral e′, cm/s | 7.3 ± 1.8 | 7.5 ± 1.8 | 7.0 ± 1.7 | 0.021 |
| Average mitral E/e′ ratio | 11 ± 5 | 10 ± 5 | 13 ± 6 | <0.001 |
| Grade I/II/III diastolic dysfunction ( | 155/83/10 | 127/54/5 | 28/29/5 | 0.003 |
| Positive variables of left ventricular diastolic function | 2.6 ± 0.7 | 2.4 ± 0.6 | 2.8 ± 0.7 | <0.001 |
| 0–1/2/3/4 | 0/176/109/37 | 0/130/48/15 | 0/46/61/22 | <0.001 |
| Right ventricular function | ||||
| Right atrial end‐systolic area, cm2 ( | 15 ± 6 | 13 ± 4 | 18 ± 8 | <0.001 |
| RVOT, mm | 26 ± 5 | 25 ± 5 | 27 ± 5 | 0.002 |
| RVSP, mmHg | 33 ± 11 | 31 ± 11 | 36 ± 11 | <0.001 |
| TAPSE, mm ( | 20 ± 4 | 21 ± 4 ( | 18 ± 3 ( | <0.001 |
| RVFAC, % ( | 48 ± 12 | 53 ± 9 ( | 42 ± 13 ( | <0.001 |
| E/A ratio of tricuspid inflow ( | 1.2 ± 0.3 | 1.1 ± 0.3 ( | 1.3 ± 0.4 ( | 0.019 |
| DT of tricuspid early inflow, ms ( | 182 ± 55 | 198 ± 50 ( | 153 ± 54 ( | <0.001 |
| Tricuspid e′, cm/s ( | 10 ± 4 | 11 ± 4 ( | 9 ± 3 ( | 0.064 |
| Tricuspid E/e′ ratio ( | 5.4 ± 2.4 | 4.6 ± 1.2 ( | 6.8 ± 3.0 ( | 0.002 |
| IVC, mm | 15 ± 5 | 14 ± 4 | 16 ± 5 | <0.001 |
Data are number of patients (%) or mean ± SD. DT, deceleration time; IVC, inferior vena cava; LAVI, left atrial volume index; LVEDD, left ventricular end‐diastolic dimension; LVEF, left ventricular ejection fraction; RVFAC, right ventricular fractional area change; RVOT, right ventricular outflow tract; RVSP, right ventricular systolic pressure; TAPSE, tricuspid annular systolic excursion.
Multivariate analysis of cardiovascular events
| Univariate | Final model using stepwise backward reduction | |||||
|---|---|---|---|---|---|---|
| Odds ratio | 95% confidence interval |
| Odds ratio | 95% confidence interval |
| |
| Age (per 1 year) | 1.076 | 1.048–1.104 | <0.001 | 1.029 | 1.002–1.057 | 0.038 |
| Men | 0.696 | 0.434–1.117 | 0.133 | |||
| Heart rate (per 1 b.p.m.) | 1.008 | 0.987–1.030 | 0.459 | |||
| Prior hospitalization for HFpEF | 5.223 | 3.271–8.338 | <0.001 | 3.185 | 1.956–5.186 | <0.001 |
| Hypertension | 2.572 | 0.939–7.047 | 0.066 | |||
| Diabetes Mellitus | 1.13 | 0.649–1.969 | 0.666 | |||
| Chronic atrial fibrillation | 2.745 | 1.71–4.407 | <0.001 | |||
| Prior coronary revascularization | 0.779 | 0.452–1.342 | 0.369 | |||
| Beta‐blockers | 0.952 | 0.601–1.506 | 0.832 | |||
| Calcium channel blockers | 1.194 | 0.750–1.899 | 0.455 | |||
| ACE/ARB inhibitors | 1.354 | 0.795–2.306 | 0.264 | |||
| Diuretics | 5.064 | 2.823–9.083 | <0.001 | 2.187 | 1.141–4.190 | 0.018 |
| NYHA III | 4.706 | 2.946–7.519 | <0.001 | 1.832 | 1.100–3.049 | 0.020 |
| LVEF (per 1%) | 0.976 | 0.948–1.001 | 0.063 | |||
| LVEDD (per 1 mm) | 0.990 | 0.948–1.033 | 0.636 | |||
| LAVI (per 1 mL/m2) | 1.029 | 1.010–1.048 | 0.002 | |||
| Average mitral E/e′ ratio | 1.058 | 1.024–1.094 | <0.001 | |||
| RVOT (per 1 mm) | 1.014 | 0.970–1.059 | 0.547 | |||
| RVSP (per 1 mmHg) | 1.047 | 1.031–1.062 | <0.001 | 1.032 | 1.012–1.052 | 0.002 |
| IVC (per 1 mm) | 1.107 | 1.059–1.158 | <0.001 | |||
| Less‐distensible right ventricle | 3.554 | 2.185–5.781 | <0.001 | 2.046 | 1.237–3.385 | 0.005 |
ACE/ARB, angiotensin‐converting enzyme inhibitors/angiotensin‐receptor blockers; HFpEF, heart failure with preserved left ventricular ejection fraction; IVC, inferior vena cava; LAVI, left atrial volume index; LVEDD, left ventricular end‐diastolic dimension; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; RVOT, right ventricular outflow tract; RVSP, right ventricular systolic pressure.
Figure 4Kaplan–Meier curves for event‐free rates according to right ventricular distensibility and right ventricular systolic pressure. The patients with a less‐distensible right ventricle and elevated right ventricular systolic pressure had the lowest event‐free rate among the four groups. RVSP, right ventricular systolic pressure.